Drug Profile
Research programme: cancer therapeutics - GlaxoSmithKline/OCTC
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Oncology Clinical and Translational Consortium
- Class Antineoplastics; Diagnostic agents
- Mechanism of Action DNA modulators; Immunomodulators; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Canada
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in France
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Netherlands